June 21, 2024 at 9:46 am

Alto Neuroscience Initiates Study of Transdermal Treatment for Schizophrenia

Alto Neuroscience (NYSE: ANRO) has initiated a Phase 2 double-blind, placebo-controlled study of a transdermal formulation of ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). The study is Alto’s sixth Phase 2 study across its pipeline programs. Alto’s cross-over double-blind, placebo-controlled, dose-escalating study will enroll approximately 70 adult participants with schizophrenia and… [Read More]
June 21, 2024 at 8:48 am

Enlivex Reports Positive Data in Knee Osteoarthritis Study

Immunotherapy company, Enlivex Therapeutics (Nasdaq: ENLV), has released positive data from its Phase 1/2 investigator-initiated clinical trial of AllocetraTM in patients with end-stage knee osteoarthritis. The study’s three-month data showed a significant reduction in pain and a favorable safety profile. The AllocetraTM injection was successful in patients with severe osteoarthritis of the knee that had… [Read More]
June 20, 2024 at 4:04 pm

Vaxxinity’s “Groundbreaking” Exploratory Data in Parkinson’s Disease Published in Nature Medicine

Vaxxinity, Inc (Nasdaq: VAXX) topped the PRISM Global Health Index on Thursday with a 14.92% rise in its share price. The market reacted favorably to the company’s announcement that groundbreaking exploratory data from its Phase 1 clinical trial of UB-312 in patients with Parkinson’s disease has been published in Nature Medicine. UB-312 is an active… [Read More]
June 20, 2024 at 2:47 pm

Tonix Pharmaceuticals Gets FDA Nod to Advance Fibromyalgia Treatment

Shares in biopharmaceutical company, Tonix Pharmaceuticals (Nasdaq: TNXP), climbed on Thursday morning after the company announced that it had successfully completed a positive pre-NDA Chemistry, Manufacturing, and Controls (CMC) meeting with the FDA. Based on formal written feedback, Tonix believes it is aligned with the FDA on key topics, including proposed drug substance and drug… [Read More]
June 20, 2024 at 1:44 pm

While Rory Continues to Chase a Major Win, Topgolf Callaway (MODG) Makes Major Moves Inking Multi-Year Agreement with Visa (V)

While Bryson DeChambeau drinks wine out of his newly won US Open trophy and Rory contemplates scorching Pinehurst’s 18th hole, TopGolf Callaway Brands Corp. (MODG) made moves of their own and announced their entrance into a partnership with Visa, Inc. (V). This partnership provides co-promotional opportunities and card holder benefits that will begin this summer… [Read More]
June 20, 2024 at 10:12 am

Intra-Cellular Therapies Offers New Hope for Treating Depression

Shares in Intra-Cellular Therapies (Nasdaq: ITCI) rose 9.60% on Tuesday to reach $75.48 after the company announced positive topline data from a study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). The study achieved statistically significant and clinically meaningful results in both the primary and… [Read More]
June 18, 2024 at 5:37 pm

The GLP-1 Gold Rush Continues

A 2024 report from GlobalData has revealed that in spite of approaching headwinds in the obesity market, glucagon-like peptide-1 (GLP-1) receptor agonists will continue to generate blockbuster sales. The analysis projected that sales will reach a total value of $111 billion by 2033 after achieving $25 billion in 2023 in the US, France, Spain, Germany,… [Read More]